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Abstract Breast cancer patients are at increased risk of
sexual dysfunction. Despite this, both patients and practi-
tioners are reluctant to initiate a conversation about sexu-
ality. A sexual dysfunction screening tool would be helpful
in clinical practice and research, however, no scale has yet
been identified as a ‘‘gold standard’’ for this purpose. The
present review aimed at evaluating the scales used in breast
cancer research in respect to their psychometric properties
and the extent to which they measure the DSM-5/ICD-10
aspects of sexual dysfunction. A comprehensive search of
the literature was conducted for the period 1992–2013,
yielding 129 studies using 30 different scales measuring
sexual functioning, that were evaluated in the present
review. Three scales (Arizona Sexual Experience Scale,
Female Sexual Functioning Index, and Sexual Problems
Scale) were identified as most closely meeting criteria for
acceptable psychometric properties and incorporation of
the DSM-5/ICD-10 areas of sexual dysfunction. Clinical
implications for implementation of these measures are
discussed as well as directions for further research.
Keywords Breast neoplasms  Sexual dysfunction 
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Introduction
Breast cancer is the second most common cancer world-
wide and the most commonly diagnosed female cancer [1].
With high 5-year survival rates (76–92 %) there are
increasing numbers of breast cancer survivors [2], leading
to a focus on aspects of quality of life (QOL) [3], due to the
long-term effects of cancer and its treatment [4, 5]. Most
women (50–75 %) diagnosed with breast cancer report
persistent difficulties with sexual functioning [6–8]. Bio-
logical, psychological, and social factors all contribute to
the development of this sexual dysfunction [9]. Neglecting
to address these issues may contribute to further distress
and relationship difficulties, and possibly impact other
aspects of women’s lives [10].
Sexual assessment and counseling are not routinely
provided in oncological settings [11], with less than one-
third of breast cancer patients reporting having discussed
sexuality concerns with a healthcare professional [12], of
these few report satisfaction with the consultation [12], and
generally these discussions only occur if the medical
practitioner raises the subject [13]. Practitioners’ reluctance
to initiate these conversations may stem from fears of lit-
igation and over-involvement in non-medical issues,
embarrassment, and misleading assumptions held about
their patients’ priorities for treatment [14].
Considering the barriers to discussing these issues, an
easily administered, reliable, and valid scale measuring
sexual functioning may be useful as a screening tool and to
help facilitate clinic-based conversations. In research, such
a scale may be used to quantify treatment outcomes and
side effects. It is important that any such measure incor-
porates all dimensions of sexual dysfunction, as defined by
internationally accepted diagnostic criteria, Diagnostic and
Statistical Manual of Mental Disorders, DSM-5 [15] and
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International Classification of Diseases and Related Health
Problems, ICD-10 [16]. These dimensions include desire to
have sexual activity, excitement/arousal, orgasm, pain, and
distress/dysfunction.
To date, there have been three published reviews of
scales measuring sexual functioning in individuals with
cancer [10, 17, 18], none of which specifically focused on
breast cancer, which requires separate consideration
because (1) breasts are considered symbols of sexuality and
feminism in Western cultures, which may lead to adverse
impact of breast cancer and treatment on women’s femi-
nine and sexual identity [19]; (2) women report reduced
sexual arousal from breast stimulation following breast
surgery [20]; and (3) women may experience diminished
sexual responsiveness due to hormonal treatments used for
managing breast cancer [21].
Prior reviews are also limited in that they: do not reflect
current research in this area [17]; reviewed a select number of
measures [18]; focused on measures used in all cancers,
rather than breast cancer specifically [10, 17, 18]; and,
neglected to include sexual functioning subscales incorpo-
rated within QOL measures [10, 17, 18], which are often used
in treatment outcomes research. Additionally, no reviews
have delineated the extent to which the scales incorporate the
DSM-5/ICD-10 dimensions of sexual dysfunction.
Unfortunately very few scales used in breast cancer
research have actually been validated on this population. For
this reason, our review will delineate the psychometric
properties of scales applied within this context. Only self-
report measures were considered since they are easy to
administer, relatively cost-effective, and may be less intru-
sive than other modes of assessment [22]. The specific aims
were to: (1) evaluate the psychometric properties of available
measures; and (2) evaluate the extent to which these mea-
sures incorporate DSM-5/ICD-10 sexual dysfunction crite-
ria. The psychometric properties reviewed included
reliability, validity and responsiveness to change. The defi-
nitions of these terms, methods of measurement and psy-
chometric evaluation criteria are presented in Table 1. As
sexual dysfunction is a sensitive subject, the patients’
acceptability of scale questions was also evaluated.
Materials and methods
Search strategy
Literature searching using CINAHL, Embase, MEDLINE,
PsycINFO, PubMed from 1992 to 2013 was conducted
using the terms ‘‘breast cancer,’’ ‘‘breast neoplasms’’,
‘‘sexual functioning,’’ and ‘‘sexual dysfunction.’’ The
search was limited to empirical studies published in Eng-
lish language peer-reviewed journals.
Inclusion and exclusion criteria
The review inclusion and exclusion criteria are listed in
Table 2. Where the title or abstract indicated that exclusion
criteria were met, the study was rejected. Full text articles
were accessed when: (1) it was not clear from the title or
abstract whether the inclusion criteria were met or what
sexual functioning scale was used; and, (2) inclusion criteria
were met and the empirical studies for scales were reviewed.
Scale evaluation scoring system
Each included scale was assessed using the following criteria:
(1) psychometric properties; and (2) coverage of DSM-5/ICD-
10 dimensions of sexual dysfunction [15, 16]. A score was
assigned to each scale indicating the extent to which it had
adequate psychometric properties and covered the dimensions
of sexual dysfunction (see Table 1 for scoring system).
Additional points were awarded based on the characteristics of
the validation sample, where ‘‘1’’ was given to studies where
n [ 300, as this is recommended for scale validation [23], and
‘‘0.5’’ where sample sizes were between 200 and 299. Since
scale psychometric properties are dependent on the population
studied [24], ‘‘1’’ was given if the validation sample included
women with breast cancer, and ‘‘0.5’’ if it included cancer
patients generally. Scores for the extent to which the DSM-5/
ICD-10 dimensions of sexual dysfunction were incorporated
were: ‘‘1’’ for each time at least one question covered one of
the five domains (Desire, Arousal, Orgasm, Pain, Distress),
with a maximum score of 5. Scores for all quality criteria were
summed, with a maximum score of 17 (i.e., 12 psychometric
property points and 5 for DSM-5/ICD-10 criteria). The first
author (IB) rated the measures first, followed by the second




The literature search results are presented in Fig. 1. Out of
the 2,192 citations initially identified, 129 studies met the
inclusion criteria, using 30 different scales, 18 of which
were specifically designed to measure sexual functioning,
and 12 were subscales within QOL questionnaires. For the
latter, only psychometric properties for sexual functioning
subscales were reviewed.
Evaluation of sexual functioning scales
The evaluation of the sexual functioning scales is presented
in Tables 3 and 4. Where multiple validation studies for the
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same scale existed, the results were differentiated by
assigning a number in their subscript (e.g., n1, n2, denotes
sample sizes in two different studies).
Validation sample characteristics
Only four scales (13 %) met the criteria of having adequate
sample size and containing women diagnosed with breast
cancer (BCPT-SCL [25], CARES [26] Sexual Problem
Scale [27], WHOQOL-100 [28]).
Reliability
Seven scales (23 %) met the reliability criteria, that is,
having both adequate internal consistency and temporal
stability: ASEX [29], FSFI [30], Sexual Self-Schema Scale
Potentially relevant 






Duplicates removed (237) 
Potentially relevant 
publications (1955) 
Excluded based on  
Title (1366) and Abstract 
(347) relevance
Full text accessed  (242) 
Excluded studies (113) 
Reasons: 
Did not contain validated measure of sexual functioning (30) 
Did not include a measure of sexual functioning (26) 
Questions asked were not part of the scale (21) 
Not a self-report measure (11) 
Review articles (8) 
Scale was not available or validated in English (6) 
Did not include information about scales used (6) 
Did not include women diagnosed with breast cancer (4) 
Research focused on partners (1) 
Studies included (129) 
Scales used  (30) 
Fig. 1 Flowchart of the
systematic review
Table 2 Study inclusion and exclusion criteria
Criterion Included Excluded
Type of study Original study Review paper
Quantitative Qualitative
Type of scales Self-report Other
Population studied Women diagnosed with
breast cancer
Other populations, including women at risk of developing breast cancer and women
diagnosed with Ductal Carcinoma in Situ




Partners, care providers and professionals
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[31], and the sexual functioning subscales of the CARES
[26], MRS [32], QLACS [33], and WHOQOL-100 [28].
Validity
No scales were awarded full scores (6) for their validity
studies, but those with the greatest validity evidence (C4)
included: CSDS [58], FSFI [30], Heatherington Intimate
Relationship Scale [34], Sexual Self-Schema Scale [31],
SQoL-F [67], MRS [32], and WHOQOL-100 [28].
Responsiveness to change
Only five (17 %) scales included evidence of responsive-
ness to change (ASEX [29], BIRS [36] (GRISS) [37]
BCPT-SCL [25], MENQOL [35]). ASEX and BIRS were
able to detect improvements in sexual functioning due to
treatment (positive change), BCPT-SCL deterioration of
functioning due to breast cancer treatment (negative
change), and MENQOL and GRISS clinically meaningful
change, regardless of direction.
Acceptability to participants
Only four (13 %) of the scales included information on the
degree to which the scale questions are acceptable to the par-
ticipants (GRISS [37], SAQ [38], CARES [26], QLACS [33]).
DSM-IV-TR/ICD-10 aspects
No scales assessed all five aspects of DSM-IV-TR/ICD-10
female sexual dysfunction. FSFI [30], MFSQ [39], SHF
[40], Sexual Problem Scale [27] assessed four aspects,
while ASEX [29], MOS-SF [41], SAQ [38], Watt’s Sexual
Functioning Scale [42], WSBQ-F [43] assessed three.
Overall scores
The overall scores ranged from 2 to 11. The three scales
with the highest scores included: FSFI [30] (11), Sexual
Problem Scale [27] (10.5), and ASEX [29] (10).
Discussion
Our review has indicated that no one scale obtained full
score, indicating superior psychometric properties and
coverage of all DSM-5/ICD-10 areas of sexual dysfunction
(desire, arousal, orgasm, pain, distress), which is consistent
with previous reviews in oncology [10, 17] and general
populations [44, 45]. Three highest scoring scales included
ASEX, FSFI and Sexual Problems Scale. While FSFI has
previously been identified as a good quality scale [10, 18],
our review also identified two other scales of similar
quality (ASEX, Sexual Problems Scale). In the absence of
a ‘‘gold standard’’ sexual dysfunction measure, we rec-
ommend that any of these three scales are suitable for use
in the breast cancer context, with specific caveats outlined
below.
When selecting a measure of sexual dysfunction to use in
clinical practice or research, there are three considerations:
(1) psychometric properties, to ensure that the variability in
scores observed is reflective of the variability in the under-
lying construct, rather than measurement error [24]; (2) how
well the scale measures the construct of interest (DSM-5/
ICD-10 aspects of sexual dysfunction); and (3) practical
issues (administration, scoring, interpretation).
Only the Sexual Problems Scale has been validated on
an adequate-sized breast cancer sample, where it demon-
strated good internal consistency and evidence of validity.
However, no test–retest data are available, making it less
useful for repeated measures. ASEX has been validated on
general and psychiatric populations. The FSFI has been
validated on community, sexual dysfunction, and gyneco-
logic cancer samples. Hence, for one-off measurement of
sexual dysfunction we recommend the Sexual Problems
Scale, and for repeated measures the ASEX or FSFI may be
more useful.
DSM-5/ICD-10 criteria incorporate when women
experience distress due to painful sexual encounters, or
disruption in desire, arousal or orgasm. None of the three
preferred scales include items measuring distress, and
ASEX also does not include items measuring pain; hence,
FSFI and the Sexual Problems Scale are recommended as
they have the greatest coverage of the DSM-5/ICD-10
dimensions of sexual dysfunction. Additional information
about the levels of distress may need to be collected to
supplement these scales.
All three scales are relatively brief (ASEX-5, FSFI-19,
and Sexual Problems Scale-9 items, respectively) and
readily accessible. As yet, these scales do not have elec-
tronic versions for ease of administration and scoring. To
obtain a total score, ASEX and the Sexual Problems Scale
have individual items summed, whereas FSFI’s scoring
algorithm is more complex with six subscales being sum-
med to yield a total score. All scales can be interpreted to
identify potential areas of sexual dysfunction, and the
Sexual Problems Scale also takes into account partner
variables (i.e., lack of interest in sex). Additionally, FSFI
can only be validly interpreted for individuals experiencing
sexual activity in the past month. Therefore, the Sexual
Problems Scale is considered most practical, as it is rela-
tively short to administer and score, and it can identify
when dysfunction is due to partner difficulties.
This review also highlighted ways in which existing
measures can be improved. To make these scales more
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psychometrically meaningful for breast cancer population,
they would benefit from replication of validation studies in
this context. Future research should focus on demonstrating
concurrent validity, as many validation studies did not
report these data. Demonstrating concurrent validity is
more difficult when there is no acceptable ‘‘gold standard,’’
but researchers are encouraged to use the three scales
identified above for this purpose. Generally, all scales can
be further improved by additional items to ensure adequate
coverage of all dimensions aspects of sexual dysfunction
[15, 16], in particular distress. Although the evaluation of
the cultural suitability and sensitivity of scales was beyond
the scope of this review, some scales have validation data
for different languages and cultures (e.g., FSFI, MFSQ,
SAQ, EORTC-BR-23, WHOQOL-100). Future studies
should continue to investigate cross-cultural properties of
these sexual dysfunction scales.
In conclusion, this comprehensive systematic review
builds upon and extends prior work concerning sexual
dysfunction in oncology [10, 17, 18], by focusing specifi-
cally on the breast cancer context. Strengths of the research
are that it was based on a rigorous psychometric evaluation
of measures and an assessment of the extent to which
existing measures meet the diagnostic criteria for sexual
dysfunction [15, 16]. The scoring system provided a sys-
tematic way to summarize the extent to which the scales
met the psychometric and DSM-V/ICD-10 criteria. The
limitation of the review is that it focused only on studies
published in the English language, leading to possible bias.
Our conclusions are of equal importance to clinicians
and researchers alike, for whom the selection of appro-
priate measures of sexual dysfunction will facilitate clinical
consultation and discussion with patients, or as critical
outcomes and endpoints of clinical trials.
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